Nonsteroidal tissue selective androgen receptor modulators: a promising class of clinical candidates

Abstract

The androgen receptor (AR) is a nuclear hormone receptor that, upon binding to testosterone, dihydrotestosterone (DHT) and other endogenous androgens, supports the development, growth and maintenance of masculine features through activation of anabolic and androgenic metabolism. The AR has been demonstrated to be a productive therapeutic target. AR ligands in clinical practice include androgenic steroids, antiandrogenic steroids and antiandrogenic nonsteroidals. Of primary importance for this review are nonsteroidal selective AR modulators (SARMs) that have tissue-specific agonist and/or antagonist activities. The AR has a myriad of peripheral and central functions that can be modulated in a pleiotropic and tissue-specific fashion using the increasingly diverse collection of SARMs discussed herein. This suggests that SARMs will have a high level of clinical utility for a wide variety of health conditions. The patent literature focusing on SARMs is reviewed and reveals multiple chemical classes in various stages of preclinical and clinical development. Emphasis is placed on selected disease states for which SARMs show potential for therapeutic use in clinical practice.

Keywords::

• acyl anilide
• ageing
• androgen receptor (AR)
• andropause
• hypogonadism
• muscle wasting
• nonsteroidal androgen
• osteoporosis
• phthalimide
• sarcopaenia
• selective androgen receptor modulator (SARM)
• propionamide
• propionanilide
• tetrahydroquinoline
• tricyclic quinoline